Sirolimus versus cyclosporine A in patients with primary acquired pure red cell aplasia: a prospective cohort study.

Blood Cancer J · 2023 · PMC10169841 · PMID 37160872

Europe PMC DOI

hedged sentence

0.1700

closest p · 3.4× alpha

0.1700

boldest claim

The sentences

showed a trendP = 0.17not close (p > 0.1)

Additionally, patients in the sirolimus group showed a trend toward a longer relapse-free survival than patients in the CsA group ( P = 0.17, Fig. 1C ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.